HPV in oropharyngeal cancer: The basics to know in clinical practice;HPV nel carcinoma dell’orofaringe: Le nozioni base da conoscere nella pratica clinica

Acta Otorhinolaryngologica Italica

Volumn 34, Issue 5, 2014, Pages 299-309

  Elrefaey, S ^a,b   Massaro, M A ^a   Chiocca, S ^a   Chiesa, F ^a   Ansarin, Mohssen ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Clinical Trial; Head and Neck cancer; Human Papillomavirus; Oropharyngeal cancer; Prevention; Prognosis; Squamous Cell Carcinoma; Treatment; Vaccination

Indexed keywords

WART VIRUS VACCINE;

CARCINOMA, SQUAMOUS CELL; COMPLICATION; HUMAN; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; HUMANS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84983571355     PISSN: 0392100X     EISSN: 1827675X     Source Type: Journal    
DOI: None     Document Type: Article

References (101)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: globocan 2008. Int J Cancer 2010;127:2893-917.
2. Sturgis EM, Ang KK. The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms? J Natl Compr CancNetw 2011;9:665-73.
3. Johnson N, Franceschi S, Ferlay J, et al. Oral Cavity and Oropharynx. In: Barnes L, Eve J, Reichart P, et al., editors. Int. Pathology and Genetics Head and Neck Tumors. Lyon 2005. p. 163-208.
4. van Monsjou HS, Balm AJ, van den Brekel MM, et al. Oropharyngeal squamous cell carcinoma: a unique disease on the rise? Oral Oncol 2010;46:780-5.
5. Mignogna MD, Fedele S, Lo Russo L. The world cancer report and the burden of oral cancer. Eur J Cancer Prev 2004,13:139-42.
6. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.
7. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the US population ages 20-44 years. Cancer 2005;103:1843-9.
8. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papilloma virus and rising oropharyngeal cancer in the United States. J Clin Oncol 2011;29:4294.
9. Sedrak M, Rizzolo D. Understanding the link between hpv and oropharyngeal cancer. JAAPA 2009;22:42-6.
10. McKean-Cowdin R, Feigelson HS, Ross RK, et al. Declining cancer rates in the 1990s. J Clin Oncol 2000;18:2258-68.
11. Hammarstedt L, Dahlstrand H, Lindquist D, et al. The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol 2007;127:988-92.
12. Robinson KL, Macfarlane GJ. Oropharyngeal cancer incidence and mortality in Scotland: are rates still increasing? Oral Oncol 2003;39:31-6.
13. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. Natl Cancer Inst 2000;92:709-20.
14. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004;31:744-54.
15. Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010;116:2166-73.
16. Adelstein DJ, Rodriguez CP. Human papilloma virus: changing paradigm in oropharyngeal cancer. Curr Oncol Rep 2010;12:115-20.
17. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333(6046):1157-1160.
18. Oh JE, Kim JO, Shin JY. Molecular genetic characterization of p53 mutated oropharyngeal squamous cell carcinoma cells transformed with human papillomavirus E6 and E7 oncogenes. Int J Oncol 2013;43:383-93.
19. Rampias T, Sasaki C, Weinberger P. E6 and E7 gene silencing and transformed phenotype of human papillomavirus 16 - positive oropharyngeal cancer cells. J Natl Cancer Inst 2009;101:412-23.
20. National Comprehensive Cancer Center Network. Practice guidelines in oncology-Head and Neck Cancers v. 2.2008.
21. National Cancer Institute: PDQR Oropharyngeal Cancer Treatment. Bethesda, MD: National Cancer Institute. Date last modified <02/15/2013>. Available at: http://cancer.gov/ cancertopics/pdq/treatment/oropharyngeal/HealthProfessional. Accessed <02/15/2013>
22. Ansher SS, Scharf R. The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute. Ann N Y Acad Sci 2001;949:333-40.
23. Lindel K, Beer KT, Laissue J, et al. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001;92:805-13.
24. Kreimer AR, Cliffor GM, Boyle P, et al. Human papilloma virus types in head and neck squamous cell carcinomas worldwide: a systemic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-75.
25. D’Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med 2011;53(Suppl 1):S5-11.
26. Llewellyn CD, Linklater K, J Bell, et al. An analysis of risk factors for oral cancer in young people: a case-control study. Oral Oncol 2004;40:304-13.
27. Gillison Ml, D’Sousa G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positiveand human papillomavirus type 16-negativehead and neck cancers. J Natl Cancer Inst 2008;100:407-20.
28. Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus related and unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-9.
29. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
30. D’Souza G, Kreimer AR, Clifford GM, et al. Case control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56.
31. Benard VB, Johnson CJ, Thompson TD, et al. Examining the association between socioeconomic status and potential human papillomavirus associated cancers. Cancer 2008;113:2910-8.
32. Settle K, Posner MR, Schumaker LM, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) 2009;2:776-81.
33. Ryerson AB, Peters ES, Coughlin SS, et al. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 2008;113:2901-9.
34. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papilloma virus associated cancers? Cancer 2007;110:1429-35.
35. D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944.
36. Frisch M, Biggar RJ. Aetiological parallel between tonsillar and anogenital squamous-cell carcinomas. Lancet 1999;354(9188):1442-3.
37. Hemminki K, Dong C, Frisch M. Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands. Eur J Cancer Prev 2000;9:433-7.
38. Heck JE, Berthiller J, Vaccarella S, et Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol 2010;39:166-81.
39. Smith EM, Ritchie JM, Summersgill KF, et al. Age, sexual behaviour, and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004;108:766-72.
40. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous- 0cell carcinoma of the head and neck. N Engl J Med 2001;344:1125-31.
41. Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009;18:541-50.
42. Hammarstedt L, Lindquist D, Dahlstrand H, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006;119:2620-3.
43. Klussman JP, Weissenborn SJ, Wieland U, et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001;92:2875-84.
44. Joseph AW, D’Souza G. Epidemiology of human papillomavirus- related head and neck cancer. Otolaryngol Clin North Am 2012;45:739-64.
45. Chu A, Genden E, Posner M, et al. A patient centered approach to counseling patients with head and neck cancer undergoing human papillomavirus testing: a clinician’s guide. Oncologist 2013;18:180-9.
46. Syrjanen S. HPV infections and tonsillar carcinoma. J Clin Pathol 2004;57:449-55.
47. Dahlstrand HM, Dalianis T. Presence and influence of human papillomaviruses (HPV) in tonsillar cancer. Adv Cancer Res 2005;93:59-89.
48. Dahlgren L, Mellin H, Wangsa D, et al. Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomaviruspositive and -negative tumors. Int J Cancer 2003;107:244-9.
49. Lohavanichbutr P, Houck J, Fan W, et al. Genomewide gene expression profiles of HPV- positiveand HPV-negative oropharyngeal cancer: potential implications for treatment choices. Arch Otolaryngol Head Neck Surg 2009;135:180-8.
50. Smeets SJI, Braakhuis BJ, Abbas S, et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing humanpapillomavirus. Oncogene 2006;25:2558-64.
51. Huang SH, Perez-Ordonez B, Liu FF, et al. Atypical clinical behaviour of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2012;82:276-83.
52. Goldenberg D, Begum S, Westra WH, et al. Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon. Head Neck 2008;30:898-903.
53. Chaturvedi AK. Epidemiology and clinical aspects of HPV in head and neck cancers. Head and Neck Pathol 2012;6:S16-S24.
54. Cantrell SC, Peck BW, Li G, et al. Differences in imaging characteristics of HPV-positive and HPV negative oropharyngeal cancers: A blinded matched-pair analysis. AJNR Am J Neuroradiol 2013;34:2005-9.
55. Olshan AF. Epidemiology, pathogenesis, and prevention of head and neck cancer. New York: Springer; 2010.
56. Marur S, D’Souza G, Westra WH, et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11:781-9.
57. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 2009;15:6758-62.
58. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9.
59. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010;28:4142-8.
60. Lassen P, Eriksen JG, Krogdahl A, et al. The influence of HPVassociated p16 expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol 2011;100:49-55.
61. Posner M, Lorche J, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX324: a subset analysis from an international phase III trial. Ann Oncol 2011;22:1071-7.
62. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancerpatients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 2010;16:1226-35.
63. Hafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 2008 15;122:2656-64.
64. Klussmann JP, Mooren JJ, Lehnen M, et al. Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin Cancer Res 2009;15:1779-86.
65. Lindel K, Beer KT, Laissue J, et al. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001;92:805-13.
66. Vu HL, Sikora AG, Fu S. HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett 2010:28;288:149-55.
67. Ang KK, Sturgis EM. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol 2012;22:128-42.
68. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1992-8.
69. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. HPV-associated p16- expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 2009;94:30-5.
70. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008 1;26:3128-37.
71. Rietbergen MM, Snijders PJ, Beekzada D, et al. Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas. Int J Cancer 2014;134:2366-72.
72. Bussu F, Sali M, Gallus R, et al. HPV infection in squamous cell carcinomas arising from different mucosal sites of the head and neck region. Is p16 immunohistochemistry a reliable surrogate marker? Br J Cancer 2013;108:1157-62.
73. Dowthwaite SA, Franklin JH, Palma DA, et al. The role of transoral robotic surgery in the management of oropharyngeal cancer: a review of the literature. ISRN Oncol 2012;2012:945162.
74. Moore EJ, Henstrom DK, Olsen KD, et al. Transoral resection of tonsillar squamous cell carcinoma. Laryngoscope 2009;119:508-15.
75. Park YM, Lee JG, Lee WS, et al. Feasibility of transoral lateral oropharyngectomy using a robotic surgical system for tonsillar cancer. Oral Oncol 2009;45:e62-6.
76. Genden EM, Sambur IM, de Almeida JR, et al. Human papilloma virus and oropharyngeal cell squamous cell carcinoma: what the clinician should know. Eur Arch Otorhinolaryngol 2013;270:405-16.
77. Quon H, Richmon JD. Treatment deintensification strategies for HPV-associated head and neck carcinomas. Otolaryngol Clin North Am 2012;45:845-61.
78. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous- cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44.
79. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;51:571-8.
80. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26:3582-3.
81. Cohen MA, Weinstein GS, O’Malley BW Jr, et al. Transoral robotic surgery and human papillomavirus status: Oncologic results. Head Neck 2011;33:573-80.
82. Stucken C, de Almeida JR, Tong CCL, et al. Transoral robotic surgery for smokers with squamous cell carcinoma of the oropharynx. In: Multidisciplinary Head and Neck Cancer Symposium, Phoenix, AZ; 2012.
83. Genden ER. The role of surgical management in HPV-Related oropharyngeal carcinoma. Head Neck Pathol 2012;6(Suppl 1):S98-103.
84. Goodwin EC, Yang E, Lee CJ, et al. Rapid induction of senescence in human cervical carcinoma cells. Proc Nat Acad Sci USA 2000;97:10978-83.
85. World Health Organization. Countries using Hepatitis B vaccine. [cited: July 2012]. Available from: http://www.who.int/ mediacentre/factsheets/fs204/en/.
86. Tota JE, Chevarie-Davis M, Richardson LA, et al. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med 2011;53(Suppl):S12-21.
87. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008;113:3036-46.
88. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention 2007. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm?s_ cid=rr5602a1_e (Last accessed: Nov 23, 2014).
89. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against highgrade cervical and external genital lesions. Cancer Prev Res 2009;2:868-78.
90. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV 2,Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59:626-9.
91. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1705-8.
92. Stanley M. Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol Oncol 118(Suppl):S2-7.
93. Centers for Disease Control. Fact sheet on HPV and men. [Updated: February 23, 2012]. Available from: http://www. cdc.gov/std/hpv/stdfact-hpv-andmen.htm
94. Grasso F, Negri DR, Mochi S, et al. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein. Int J Cancer 2013;132:335-44.
95. Trimble CL, Frazer IH. Development of therapeutic HPV vaccines. Lancet Oncol 2009;10:975-80.
96. Bellone S, Pecorelli S, Cannon MJ, et al. Advances in dendritic- cell-based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther 2007;7:1473-86.
97. Psyrri A, Sasaki C, Vassilakopoulou M, et al. Future directions in research, treatment and prevention of HPV-related squamouscell carcinoma of the head and neck. Head Neck Pathol 2012;6(Suppl 1):S121-8.
98. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous- cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
99. Egloff AM, Grandis JR. Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol 2008;35:286-97.
100. Boscolo-Rizzo P, Del Mistro A, Bussu F, et al. New insights into human papillomavirus-associated head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital 2013;33:77-87.
101. Mannarini L, Kratochvil V, Calabrese L, et al. Human Papilloma Virus (HPV) in head and neck region: review of literature. Acta Otorhinolaryngol Ital 2009;29:119-26.